With positive news flow on clinical development, Array Biopharma Inc. stayed busy on the partnering front, selecting Ono Pharmaceutical Co. Ltd. to license, develop and commercialize its late-stage oncology compounds, binimetinib and encorafenib, in Japan and South Korea. Array is set to receive $31.6 million (¥3.5 billion) up front and is entitled to another $156 million (¥17.3 billion) in development, regulatory and commercial milestone payments.